menu
    • menu
    [{"orgOrder":0,"company":"Neurotrope","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors)","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Neurotrope \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Neurotrope","sponsor":"Blanchette Rockefeller Neurosciences Insitute","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors)","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neurotrope \/ Blanchette Rockefeller Neurosciences Insitute","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope \/ Blanchette Rockefeller Neurosciences Insitute"},{"orgOrder":0,"company":"Neurotrope","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors)","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Neurotrope \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope \/ Undisclosed"},{"orgOrder":0,"company":"Neurotrope","sponsor":"National Institutes of Health | National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors)","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurotrope \/ National Institutes of Health | National Institute on Aging","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope \/ National Institutes of Health | National Institute on Aging"},{"orgOrder":0,"company":"Neurotrope","sponsor":"Petros Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Merger","leadProduct":"Avanafil","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurotrope \/ Neurotrope","highestDevelopmentStatusID":"15","companyTruncated":"Neurotrope \/ Neurotrope"},{"orgOrder":0,"company":"Neurotrope","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"Protein kinase C (PRKC)","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neurotrope \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope \/ National Institutes of Health"},{"orgOrder":0,"company":"Neurotrope","sponsor":"BryoLogyx Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Bryostatin-1","moa":"Protein kinase C (PRKC)","graph1":"Oncology","graph2":"IND Enabling","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neurotrope \/ BryoLogyx Inc","highestDevelopmentStatusID":"5","companyTruncated":"Neurotrope \/ BryoLogyx Inc"},{"orgOrder":0,"company":"Neurotrope","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"Protein kinase C (PRKC)","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neurotrope \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope \/ Undisclosed"},{"orgOrder":0,"company":"Neurotrope","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Bryostatin-1","moa":"Protein kinase C (PRKC)","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neurotrope \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope \/ National Institutes of Health"},{"orgOrder":0,"company":"Neurotrope","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Bryostatin-1","moa":"Protein kinase C (PRKC)","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neurotrope \/ Neurotrope","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope \/ Neurotrope"}]

    Find Clinical Drug Pipeline Developments & Deals by Neurotrope

    Menu

    Neurotrope

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Neurotrope

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Neurotrope

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : National Institutes of Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Neurotrope Announces First Patient Dosed in Long-Term Clinical Trial of Bryostatin in Alzheimer's Disease

                            Details : The new Phase 2 clinical study, which is expected to enroll approximately 100 patients, will evaluate Bryostatin-1 in the absence of Namenda® (memantine) for a six-month period, which will include two 11-week dosing cycles.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 06, 2020

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : National Institutes of Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Neurotrope

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Neurotrope

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : National Institutes of Health | National Institute on Aging

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bryostatin Treatment of Moderately Severe Alzheimer's Disease

                            Details : Bryostatin 1 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 03, 2020

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : National Institutes of Health | National Institute on Aging

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Neurotrope

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Neurotrope

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Recipient : Worldwide Clinical Trials

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Neurotrope Bioscience Announces Agreement with Worldwide Clinical Trials, to Conduct Ongoing Phase 2 Study of ...

                            Details : Neurotrope has entered into a services agreement with Worldwide Clinical Trials to support site recruitment and activation for the Company's ongoing Phase 2 study of bryostatin-1 in the treatment of moderately severe Alzheimer's disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 30, 2020

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Recipient : Worldwide Clinical Trials

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Neurotrope

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Neurotrope

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : BryoLogyx Inc

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Sy...

                            Details : BryoLogyx has entered into two agreements with Neurotrope for its preclinical data package and drug product for use of bryostatin-1 in an immuno-oncology application, and to supply Neurotrope with synthetic bryostatin-1 for use in clinical trials and com...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 10, 2020

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : BryoLogyx Inc

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Neurotrope

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Neurotrope

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : National Institutes of Health

                            Deal Size : $2.7 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Neurotrope Launches New Long-Term Clinical Trial of Bryostatin with the NIH for the Treatment of Patients with...

                            Details : The Phase 2 clinical study will be conducted in collaboration with the National Institutes of Health. The study will evaluate the long-term therapeutic effect of Bryostatin-1 in the absence of Namenda® (memantine) in patients with AD.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 28, 2020

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : National Institutes of Health

                            Deal Size : $2.7 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Neurotrope

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Neurotrope

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Avanafil

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Recipient : Petros Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, a Men's Heal...

                            Details : Petros' cornerstone product would be Metuchen's Stendra® for erectile dysfunction. Petros' pipeline would include Metuchen's recently in-licensed product H-100 for Peyronie's disease, and it would include a business development program exploring variou...

                            Product Name : Stendra

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 18, 2020

                            Lead Product(s) : Avanafil

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Recipient : Petros Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Neurotrope

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Neurotrope

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Neurotrope Provides Corporate Update After Completing Bryostatin-1 Data Analysis for Advanced Alzheimer's Dise...

                            Details : Analysis to adjust for significant baseline imbalance in severe impairment battery scores between treatment groups shows improvement in cognitive function.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 22, 2020

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Neurotrope

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Neurotrope

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Worldwide Clinical Trials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine

                            Details : Bryostatin is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            June 18, 2018

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Worldwide Clinical Trials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Neurotrope

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Neurotrope

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease

                            Details : Bryostatin 1 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 01, 2015

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Neurotrope

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Neurotrope

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Blanchette Rockefeller Neurosciences Insitute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Dis...

                            Details : Bryostatin 1 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 21, 2014

                            Lead Product(s) : Bryostatin-1

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Blanchette Rockefeller Neurosciences Insitute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth